Interstitial Lung Disease Management

Definition and Epidemiology

The prevalence of interstitial lung diseases (ILDs) ranges between 72.1 and 164.2 cases per 100,000 Europeans, with approximately 650,000 people affected in the US, according to the Autoimmunity Reviews 1

Progressive pulmonary fibrosis (PPF) causes irreversible lung damage, significant morbidity, and increased mortality, as reported in Autoimmunity Reviews 1

Fatigue is a common symptom in patients with ILDs, as noted in Autoimmunity Reviews 1
Symptoms may be absent in sedentary patients or masked by other organ involvement or comorbidities, according to Autoimmunity Reviews and American Journal of Respiratory and Critical Care Medicine 1, 2

High-resolution computed tomography (HRCT) can identify specific patterns (UIP, NSIP, etc.) and is essential for diagnosis, as stated in European Respiratory Review 3
Pulmonary function tests (PFTs) typically show a restrictive pattern with reduced FVC and DLCO, as reported in American Journal of Respiratory and Critical Care Medicine 2
Multidisciplinary discussion (MDD) involving pulmonologists, radiologists, and pathologists is essential for accurate diagnosis, according to European Respiratory Review and Autoimmunity Reviews 3, 1

Treatment should be based on the specific ILD diagnosis, disease behavior, and risk factors, as recommended by American Journal of Respiratory and Critical Care Medicine and Autoimmunity Reviews 2, 1
Multidisciplinary team collaboration is essential, particularly for CTD-ILD, according to Autoimmunity Reviews 1, 5

Systematic monitoring with short-term PFTs and repeat HRCT is recommended to determine progression rate in CTD-ILD, as stated in Autoimmunity Reviews and Praxis Medical Insights 1, 4
Smoking cessation is the single most effective intervention for smoking-related ILD, as noted in Praxis Medical Insights 4

Vaccinations (influenza, pneumococcal) are recommended to reduce the risk of respiratory infections, according to Praxis Medical Insights 4

Regular assessment of symptoms, pulmonary function, and imaging is essential, as recommended by Autoimmunity Reviews and Praxis Medical Insights 1, 4
Short-term PFTs (within 3 months) and repeat HRCT (within 6 months) should be considered to determine progression rate, according to Praxis Medical Insights 4

Delaying treatment while focusing solely on diagnostic precision rather than initiating appropriate therapy is a common pitfall, as noted in Autoimmunity Reviews 1
Failing to recognize disease progression due to infrequent monitoring is another common pitfall, according to Praxis Medical Insights 4